| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/22/2006 | US20060135525 Pyrazolopyrimidine compound and a process for preparing the same |
| 06/22/2006 | US20060135523 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
| 06/22/2006 | US20060135521 Administering racemic reboxetine or a salt thereof for inhibition of norepinephrine reuptake |
| 06/22/2006 | US20060135520 Method of treating peripheral neuropathy |
| 06/22/2006 | US20060135519 5-aryltetrazole compounds and compositions thereof |
| 06/22/2006 | US20060135516 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors |
| 06/22/2006 | US20060135508 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 06/22/2006 | US20060135502 Cyclic derivatives as modulators of chemokine receptor activity |
| 06/22/2006 | US20060135458 For use as therapeutic agents in viral infections by human and animal viruses and in cancers caused by oncogene viruses |
| 06/22/2006 | US20060135449 A NF- kappa B decoy oligodeoxynucleotide of the sequence GGATTTCCC delivered in a liposome through the carotid artery; antiischemic agents, antitumor agents; analgesics, Alzheimer's Disease; gene transfection |
| 06/22/2006 | US20060135439 Hyaluronic acid tetrasaccharide; hyaluronic acid; glucuronic acid, N-acetylglucosamine; spinal cord injury or nerve trauma |
| 06/22/2006 | US20060135437 Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| 06/22/2006 | US20060135415 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/22/2006 | US20060135412 Methods for the treatment of alzheimers disease and compositions therefore |
| 06/22/2006 | US20060135403 Therapeutic formulations for the treatment of beta-amyloid related diseases |
| 06/22/2006 | US20060135367 2,5 -Difluoro-N-isobutyl-N-(8-propyl-[1,2,4]triazolo,[1,5-c]pyrimidin-7-ylmethyl)-benzamide; gamma aminobutyric acid receptor (GABAR) agonist/antagonist; anxiolitic, antidepressant; sleep disorder, attention deficit disorder, schizophrenia or Alzheimer's dementia |
| 06/22/2006 | US20060134303 Adding fatty acid ester, a fatty acid amide, a free fatty acid or a hydrocarbon, to a mixture of a fat or an oil, being edible or for use in cosmetics; stripping and separating the environmental pollutant present in the fat or oil |
| 06/22/2006 | US20060134228 Medicine for prevention of and treatment for amyloidosis |
| 06/22/2006 | US20060134208 Controlled release and taste masking oral pharmaceutical composition |
| 06/22/2006 | US20060134192 Method of stabilizing diarylvinylene compound |
| 06/22/2006 | US20060134145 Propofol-containing fat emulsions |
| 06/22/2006 | US20060134092 Method of degrading hardly degradable protein |
| 06/22/2006 | US20060134078 Method for culturing neural stem cells using hepatocyte growth factor |
| 06/22/2006 | DE20321237U1 Pharmaceutical composition containing oxcarbazepine, having suitable release profile for once-daily administration in treatment of epilepsy, pain or alcohol withdrawal symptoms |
| 06/22/2006 | DE102004061593A1 Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung Substituted N-heterocyclic compounds and their therapeutic use |
| 06/22/2006 | DE102004061003A1 New (5'S)-4'-cyclopentyl-3'-((S)-fluoro(4-(trifluormethyl)phenyl)meth yl)-2'-isopropyl-5',8'-dihydro-6'H-spiro(cyclobutane-1,T-quinoline)- 5'-ol is cholesterol transfer protein inhibitor useful for treating e.g. dyslipidemia and stroke |
| 06/22/2006 | DE102004061002A1 New (5'S)-2',4'-dicyclopentyl -3'-9(S)-fluoro(4-(trifluoromethyl) phenyl)methyl)-5',8' -dihydro-6'H-spiro(cyclopropane-1,7'-quinoline)- 5'-ol is a cholesterol ester transfer protein inhibitor useful for treating e.g. coronary heart diseases |
| 06/22/2006 | DE102004061001A1 New spiro-cyclohexyl-pyridine compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent coronary heart diseases, hypolipoproteinemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, restenosis and obesity |
| 06/22/2006 | DE102004061000A1 New tetrahydroquinoline compounds are cholesterol ester transfer protein inhibitors useful for primary and/or secondary prevention of coronary heart disease; and for treatment and/or prevention of e.g. hypolipoproteinemia and dyslipidemia |
| 06/22/2006 | DE102004060999A1 New (S)-4-cyclohexyl-3-((S)-fluoro-(4-trifluoromethyl-phenyl)-methyl) -2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol is cholesterol ester transfer protein inhibitor useful e.g. to treat coronary heart disease |
| 06/22/2006 | DE102004060998A1 New 2,4-dicyclopentyl-3-(fluoro-(4-trifluoromethyl-phenyl)-methyl)-7, 7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent e.g. coronary heart diseases |
| 06/22/2006 | DE102004060997A1 New tetrahydroquinoline compounds are cholesterol ester transfer protein inhibitors useful for primary and/or secondary prevention of coronary heart disease; and for treatment and/or prevention of e.g. hypolipoproteinemia and dyslipidemia |
| 06/22/2006 | CA2604463A1 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents |
| 06/22/2006 | CA2592353A1 Tetrahydroisoquinoline compounds for treatment of cns disorders |
| 06/22/2006 | CA2592321A1 Nicotinic acetylcholine receptor ligands |
| 06/22/2006 | CA2592288A1 Process for the preparation of galanthamine hydrobromide |
| 06/22/2006 | CA2591621A1 Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/22/2006 | CA2591430A1 Nicotinic acetylcholine receptor ligands |
| 06/22/2006 | CA2591415A1 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | CA2591399A1 Aminocarboxylic acid derivative and medicinal use thereof |
| 06/22/2006 | CA2591397A1 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments |
| 06/22/2006 | CA2591211A1 Thieno-pyridine derivatives as gaba-b allosteric enhancers |
| 06/22/2006 | CA2591079A1 Bridged ring nk1 antagonists |
| 06/22/2006 | CA2590841A1 Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders |
| 06/22/2006 | CA2590838A1 Preventive or therapeutic agent for sleep disorder |
| 06/22/2006 | CA2590337A1 Humanized amyloid beta antibodies for use in improving cognition |
| 06/22/2006 | CA2590316A1 Bi- and tricyclic substituted phenyl methanones as glycine transporter i (glyt-1) inhibitors for the treatment of alzheimer's disease |
| 06/22/2006 | CA2590294A1 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| 06/22/2006 | CA2590287A1 Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| 06/22/2006 | CA2590229A1 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | CA2590182A1 Indolomorphinan derivatives having carboxy at the 6'-position |
| 06/22/2006 | CA2589017A1 Amyloid beta antibodies for use in improving cognition |
| 06/22/2006 | CA2588567A1 N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | CA2585560A1 Use of acetyl l-carnitine for the treatment of fibromyalgic syndrome |
| 06/22/2006 | CA2551486A1 Fused bicycloheterocycle substituted quinuclidine derivatives |
| 06/21/2006 | EP1671973A2 Allosteric adenosine receptor modulators |
| 06/21/2006 | EP1671965A2 Oxacarbocyclic oligomers of fumaric acid |
| 06/21/2006 | EP1671654A2 Conjugates of hydroxyalkyl starch and an active agent |
| 06/21/2006 | EP1670796A1 Imidazopyridine-derivatives as inducible no-synthase inhibitors |
| 06/21/2006 | EP1670791A2 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 06/21/2006 | EP1670790A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 06/21/2006 | EP1670784A1 Heteroaryl-substituted imdazole derivatives as glutamate receptor antagonists |
| 06/21/2006 | EP1670770A1 Benzimidazole derivatives, compositions containing them, preparation therof and uses thereof |
| 06/21/2006 | EP1670769A1 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| 06/21/2006 | EP1670750A1 Prodrugs of amino acids with affinity for the alpha2delta- protein |
| 06/21/2006 | EP1670479A1 The combination of a serotonin reuptake inhibitor and amoxapine |
| 06/21/2006 | EP1670471A1 Treatment of neurological disorders related to rapid eye movement (rem) sleep disturbances with npy y5 receptor antagonists |
| 06/21/2006 | EP1670469A1 Use of known active ingredients as radical scavengers |
| 06/21/2006 | EP1670466A2 Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors |
| 06/21/2006 | EP1670454A1 The combination of a serotonin reuptake inhibitor and loxapine |
| 06/21/2006 | EP1670453A2 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 06/21/2006 | EP1670450A2 Pharmaceutical compositions and method of using levodopa and carbidopa |
| 06/21/2006 | EP1670444A2 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| 06/21/2006 | EP1562576B1 Enhancement of alcohol metabolism |
| 06/21/2006 | EP1539160B1 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders |
| 06/21/2006 | EP1506193B1 Carbamate-substituted pyrazolopyridines |
| 06/21/2006 | EP1450797B1 Benzothiazole derivatives |
| 06/21/2006 | EP1401415B1 Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases |
| 06/21/2006 | EP1343526B1 Vaccine for the treatment of nicotine addiction |
| 06/21/2006 | EP1341779B1 Heterocyclic sulfonamide inhibitors of beta amyloid production |
| 06/21/2006 | EP1309322B1 Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders |
| 06/21/2006 | EP1268419B1 Pyrrolidine derivatives useful as bax inhibitors |
| 06/21/2006 | EP1255734B1 Isatine derivatives with neurotrophic activity |
| 06/21/2006 | EP1189931B1 Peptide compounds that bind her2 |
| 06/21/2006 | EP1171133B1 R-hydroxynefazodone |
| 06/21/2006 | EP1044186B9 Substituted 2-benzylamino-2-phenyl-acetamide compounds |
| 06/21/2006 | EP1025106B1 Allosteric adenosine receptor modulators |
| 06/21/2006 | EP0971601B1 Decaffeinated mate extracts and the use thereof |
| 06/21/2006 | EP0932398B1 Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders |
| 06/21/2006 | EP0920316B1 Treatment of manic disorders |
| 06/21/2006 | EP0661973B1 Method of preventing nmda receptor complex-mediated neuronal damage |
| 06/21/2006 | EP0613560B2 A method for assaying and treating alzheimer's disease |
| 06/21/2006 | CN1792021A DC motor |
| 06/21/2006 | CN1791600A Benzothiazole derivatives as adenosine receptor ligands |
| 06/21/2006 | CN1791594A 2-aminoquinoline derivative |
| 06/21/2006 | CN1791430A Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines |
| 06/21/2006 | CN1791423A Treatment of alzheimer's disease |
| 06/21/2006 | CN1791422A Use of clusterin for the treatment and/or prevention of peripheral neurological diseases |
| 06/21/2006 | CN1791416A Glycosaminoglycans for treating emotional dysfunctions |
| 06/21/2006 | CN1791412A Novel compounds and their use in therapy |